Gastroesophageal junction adenocarcinoma

Area of Science:

• Oncology
• Gastroenterology
• Surgical Oncology

Background:

• The incidence of adenocarcinoma of the esophagogastric junction (AEG) is rising globally.
• AEG often presents with advanced disease, leading to poor survival rates due to frequent lymph node or visceral metastases.
• Early-stage AEG, identified through screening for gastroesophageal reflux and Barrett's esophagus, can be treated effectively with surgery alone.

Purpose of the Study:

• To review current treatment strategies for adenocarcinoma of the esophagogastric junction (AEG).
• To evaluate the efficacy of various treatment modalities for early-stage, locally advanced, and metastatic AEG.
• To provide an overview of the evolving standard of care for AEG based on recent clinical trial data.

Main Methods:

• Literature review of clinical trials and treatment guidelines for AEG.
• Analysis of survival data for different stages and treatment approaches.
• Evaluation of neoadjuvant and adjuvant therapies, including chemoradiotherapy and surgery.

Main Results:

• Early-stage AEG (T1N0-T2N0) shows high cure rates with surgery alone.
• Preoperative chemoradiotherapy shows promise for AEG types I and II, but requires further large-scale studies for confirmation.
• Postoperative chemoradiotherapy is now standard for AJCC stage II and III gastric adenocarcinoma, including AEG type III, demonstrating improved survival.

Conclusions:

• Treatment for AEG should be stage-specific, ranging from surgery for early disease to multimodal approaches for advanced stages.
• Postoperative chemoradiotherapy has emerged as a standard of care for locally advanced gastric adenocarcinoma and AEG type III.
• Further research, particularly large randomized trials, is needed to optimize treatment strategies for AEG, especially concerning neoadjuvant therapies.